Zevra to Acquire Acer, Expanding its Rare Disease Portfolio and Adding Commercial Product

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure

Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs)

FDA-approved commercial asset expected to increase and diversify Zevra’s revenues

OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol

Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra’s rare disease clinical pipeline

Zevra to discuss details during conference call today, at 8:30 a.m. ET

Zevra will host a conference call and live audio webcast with a slide presentation today, August 31, 2023, at 8:30 a.m. ET, to discuss details of the acquisition agreement with Acer.

The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company’s website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on August 31, 2023.

Additionally, interested participants and investors may access the conference call by dialing either:

• (800) 245-3047 (U.S.)

• +1 (203) 518-9765 (International)

• Conference ID: ZevraUpdate

https://finance.yahoo.com/news/zevra-therapeutics-acquire-acer-therapeutics-113000961.html